Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WBA stock is rebounding as it expands its health care business segment. Is Walgreens stock a buy?

Is WBA Stock A Buy Or Sell In November 2022 After Major Acquisition, Q4 Earnings?

Investors shopping for income often begin by asking if a dividend, and particularly a high one, is sustainable. It's a logical and important question every investor should ask.

This Dividend Aristocrat's High Yield Looks Like a Safe Haven

Arbor Realty Trust

Amcor Plc

Ares Management

Franklin Resources

Enterprise Products Partners

Essex Property Trust

eXp World Holdings Inc

Innovative Industrial Properties

Kinder Morgan

Leggett & Platt

Main Street Capital

Medtronic

Magellan Midstream Partners

Philip Morris

Sanofi

Starwood Property

A February 2, 2022, Kiplinger Today special report headlined, "Potent Picks to Profit in 2022,” featured 97 dividend-fetching stocks from 118 in that article. Here is YCharts 11/25/22 update. Article titles were: '65 Best Dividends', '15 Value Stocks', '15 Best Mid-Caps', '10 European Plays', '9 High Yields', '6 Sturdy Defensive Stocks.'

12 Potent Picks Are December's Ideal Dividend Buys

American Electric Power Company

Gilead Sciences

Intel

Kraft Heinz

The Nasdaq has been absolutely obliterated this year, down a stunning 27%, which puts the tech-heavy index firmly in bear market territory.

Why the 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With a Santa Claus Rally

New York Community Bancorp

Omega Healthcare Investors

Owl Rock Capital Corp

PIMCO Dynamic Income Opportunities Fund

Schwab US Dividend Equity ETF

Global X S&P 500 Covered Call ETF

The Dividend Harvesting Portfolio is now generating $670.24 in annual dividends yielding 7.56%. The Dividend Harvesting portfolio has a 77.78% record of finishing the week in the black since its inception, 70/90 weeks.

Dividend Harvesting Portfolio Week 90 Update: $9,000 Allocated, $670.24 In Projected Annual Dividends

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

These Dow components, with yields ranging from 4.8% to 6.8%, are priced for opportunistic investors to pounce.

3 High-Yield Dow Jones Industrial Average Stocks That Are Screaming Buys

Walgreens Boots Alliance Inc (NASDAQ: WBA) is trading up on Tuesday after a Cowen analyst turned bullish on the Deerfield-headquartered pharmacy giant. Walgreens stock has upside to $54 The Nasdaq-listed firm has been in an uptrend since early October but Charles Rhyee is convinced that it's not out of juice just yet.

Walgreens stock price forecast: Cowen sees another 30% upside

The pharmacy giant got another upgrade from an analyst.

Why Walgreens Boots Alliance Was Trading Higher on Tuesday

Adobe

The bearishness surrounding these stocks might not last for long.

2 Beaten-Down Stocks That Could Recover in 2023

Dow Inc

The 2023 lineup of Dogs seems to face thornier problems than in years past. Here are five names to watch for those who adhere to this decades-old income-and-value strategy.

Dogs of the Dow 2023: 5 Dividend Stocks to Watch

Alliance Resource Partners

These top-notch income stocks, with yields ranging from 4.7% to 9%, can triple your money over the next decade.

3 High-Yield Dividend Stocks That Can Turn $333,000 Into $1 Million by 2032

Shares of Walgreens Boots Alliance Inc. WBA, -0.64% rallied 1.6% in premarket trading Friday, after J.P. Morgan turned bullish on the drugstore chain and healthcare services company, citing expected benefits from the company's "transformational consumer-centric healthcare strategy.

Walgreens stock rallies after J.P. Morgan turns bullish, citing 'transformational' healthcare strategy

Boeing

The Dow Jones Industrial Average is a stock index comprised of 30 of the largest, most widely held blue-chip stocks in America. Inclusion in the “Dow 30” is considered to be prestigious and a sign that a company is a leading business.

3 Dow Stocks to Sell Right Now

CVS Health

CVS and WBA are easily the two largest pharmacies in the US. CVS has performed much better than WBA over the last five years.

CVS Vs. Walgreens: Which Is The Better Investment Option Based On 2022 Results?

AbbVie

JPMorgan Chase & Co

Medical Properties Trust

Nutrien

Procter & Gamble

Stellantis N.V. 

Target

A roller-coaster year has sent a lot of deserving names into bargain territory. Here are nine value stocks for investors to consider as we head into 2023.

9 Best Value Stocks to Buy Now

Walgreens Boots Alliance, Inc. CEO Rosalind Brewer is in the midst of turning around the company to be more of a healthcare company. Walgreens shares are down over 20% on the year.

Walgreens Boots Alliance: A Great Dividend, A Better Turnaround Story

In this volatile market environment, some sleepy stocks have managed to outperform mighty Amazon.

1 Dividend Stock That's Beating Amazon (For Now) And 1 That Probably Never Will Again

WBA raises U.S. Healthcare segment revenue forecast for fiscal year 2025 from $11.5B to $15.25B. Adjusted EBITDA for the same period is raised from $600M to $1.1B. Higher interest rates may create difficulties in refinancing debt.

Walgreens Boots Alliance: Raising Guidance, Rising Share Price

Walgreens Boots Alliance (Nasdaq: WBA) and VillageMD today announced the opening of the first Village Medical at Walgreens primary care practice in Las Vegas, with more scheduled to open in the market by the end of this year.

Walgreens and VillageMD Expand Full-Service Primary Care Practices to Las Vegas

Walgreens Boots Alliance, Inc. (NASDAQ:WBA ) Credit Suisse 31st Annual Healthcare Conference November 9, 2022 2:00 PM ET Company Participants Roz Brewer - CEO James Kehoe - CFO Conference Call Participants A.J. Rice - Crédit Suisse A.J.

Walgreens Boots Alliance, Inc. (WBA) Presents at Credit Suisse 31st Annual Healthcare Conference (Transcript)

Healthpeak Properties Inc

Realty Income Corp

These three stocks can give you stable income without sacrificing long-term growth potential.

3 Dividend Stocks That Can Help You Sleep Better in a Bear Market

In a turbulent market, investors need to be aware of strengths and weaknesses with particular companies.

Wall Street's Making Big Calls on These 2 Dow Stocks

UnitedHealth Group

Are these the top health care stocks to invest in this month?

2 Healthcare Stocks To Watch In November 2022

Deutsche Bank upgraded Walgreens Boots Alliance Inc (NASDAQ:WBA) to "buy" from "hold" this morning, and raised its price target to $50 from $41, after citing a meeting with management that left the firm confident in the blue-chip name's ability to provide  healthcare services.

Walgreens Boots Alliance Stock Pops on Upgrade

Alphabet

Tesla

There have been more than 50 changes to the Dow since 1896. Removing these three established companies could be next on the docket.

News for Walgreens Stock (WBA)